이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Clínica Las Condes 미래 성장

Future 기준 확인 0/6

현재 Clínica Las Condes 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.

주요 정보

n/a

수익 성장률

n/a

EPS 성장률

Healthcare 수익 성장	29.0%
매출 성장률	n/a
향후 자기자본 수익률	n/a
애널리스트 커버리지	None
마지막 업데이트	n/a

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Is Clínica Las Condes (SNSE:LAS CONDES) A Risky Investment?

Jul 02

Returns On Capital At Clínica Las Condes (SNSE:LAS CONDES) Paint A Concerning Picture

Apr 30

Clínica Las Condes S.A.'s (SNSE:LAS CONDES) Business Is Yet to Catch Up With Its Share Price

Mar 28

Returns On Capital At Clínica Las Condes (SNSE:LAS CONDES) Paint A Concerning Picture

Jan 12

Is Clínica Las Condes (SNSE:LAS CONDES) A Risky Investment?

Oct 24

Returns At Clínica Las Condes (SNSE:LAS CONDES) Are On The Way Up

Sep 27

Clínica Las Condes (SNSE:LAS CONDES) Is Experiencing Growth In Returns On Capital

Jun 21

Clínica Las Condes (SNSE:LAS CONDES) Takes On Some Risk With Its Use Of Debt

May 19

Clínica Las Condes (SNSE:LAS CONDES) Is Doing The Right Things To Multiply Its Share Price

Aug 25

There's Been No Shortage Of Growth Recently For Clínica Las Condes' (SNSE:LAS CONDES) Returns On Capital

Apr 20

Is Clínica Las Condes (SNSE:LAS CONDES) Using Too Much Debt?

Mar 10

There's Been No Shortage Of Growth Recently For Clínica Las Condes' (SNSE:LAS CONDES) Returns On Capital

Oct 07

A Look At The Fair Value Of Clínica Las Condes S.A. (SNSE:LAS CONDES)

Aug 28

Does Clínica Las Condes (SNSE:LAS CONDES) Have A Healthy Balance Sheet?

May 31

Some Investors May Be Worried About Clínica Las Condes' (SNSE:LAS CONDES) Returns On Capital

Apr 16

A Look At Clínica Las Condes' (SNSE:LAS CONDES) Share Price Returns

Mar 12

Clínica Las Condes (SNSE:LAS CONDES) Takes On Some Risk With Its Use Of Debt

Feb 05

Should You Be Impressed By Clínica Las Condes' (SNSE:LAS CONDES) Returns on Capital?

Jan 01

Clínica Las Condes'(SNSE:LAS CONDES) Share Price Is Down 36% Over The Past Five Years.

Nov 27

이 섹션에서는 일반적으로 투자자가 회사의 수익 창출 능력을 이해하는 데 도움이 되도록 전문 애널리스트의 컨센서스 추정치를 기반으로 수익 및 수익 성장 전망치를 제시합니다. 하지만 Clínica Las Condes 은 충분한 과거 데이터를 제공하지 않았고 애널리스트 예측도 없기 때문에 과거 데이터를 추정하거나 애널리스트 예측을 사용하여 미래 수익을 안정적으로 계산할 수 없습니다.

SimplyWall St에서 다루는 기업의 97%가 과거 재무 데이터를 가지고 있기 때문에 이는 매우 드문 상황입니다.

수익 및 매출 성장 예측

SNSE:LAS CONDES - 애널리스트의 미래 추정치 및 과거 재무 데이터 (CLP Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2024	198,852	-2,146	8,110	12,433	N/A
12/31/2023	202,263	-3,401	7,991	13,589	N/A
9/30/2023	211,636	-3,614	10,542	18,272	N/A
6/30/2023	225,539	-1,240	26,211	35,639	N/A
3/31/2023	245,360	647	37,113	47,320	N/A
12/31/2022	259,992	4,047	37,205	49,213	N/A
9/30/2022	271,371	939	47,308	58,684	N/A
6/30/2022	279,943	8,916	36,052	46,376	N/A
3/31/2022	282,389	13,362	39,361	49,566	N/A
12/31/2021	276,854	18,417	29,900	37,601	N/A
9/30/2021	269,279	28,622	25,322	30,999	N/A
6/30/2021	248,857	19,437	18,136	22,066	N/A
3/31/2021	220,659	4,933	644	3,216	N/A
12/31/2020	212,266	-5,280	11,622	15,822	N/A
9/30/2020	202,808	-12,095	10,114	15,277	N/A
6/30/2020	209,306	-7,451	18,590	24,333	N/A
3/31/2020	224,860	1,750	22,405	29,031	N/A
12/31/2019	226,194	5,219	15,660	20,066	N/A
9/30/2019	227,965	8,375	25,815	29,195	N/A
6/30/2019	226,087	7,081	27,989	30,625	N/A
3/31/2019	224,119	4,778	13,992	16,806	N/A
12/31/2018	219,400	4,505	10,237	16,241	N/A
9/30/2018	206,418	-4,676	7,367	16,168	N/A
6/30/2018	203,297	-5,581	-4,785	8,939	N/A
3/31/2018	198,778	-5,100	4,985	24,030	N/A
12/31/2017	194,920	-10,346	N/A	25,341	N/A
9/30/2017	195,766	-9,252	N/A	21,246	N/A
6/30/2017	199,616	-5,559	N/A	8,245	N/A
3/31/2017	197,397	-3,258	N/A	3,253	N/A
12/31/2016	196,473	1,500	N/A	-7,191	N/A
9/30/2016	195,806	5,303	N/A	-20,704	N/A
6/30/2016	188,904	5,370	N/A	-4,569	N/A
3/31/2016	183,305	4,374	N/A	-5,973	N/A
12/31/2015	178,054	5,270	N/A	428	N/A
9/30/2015	174,007	7,929	N/A	9,025	N/A
6/30/2015	165,973	9,217	N/A	14,562	N/A
3/31/2015	160,604	12,272	N/A	15,747	N/A
12/31/2014	156,386	14,227	N/A	22,725	N/A
9/30/2014	151,772	17,275	N/A	24,894	N/A
6/30/2014	146,840	17,629	N/A	21,381	N/A
3/31/2014	142,837	18,135	N/A	23,327	N/A
12/31/2013	138,851	18,104	N/A	20,125	N/A
9/30/2013	136,462	17,669	N/A	20,475	N/A

애널리스트 미래 성장 예측

수입 대 저축률: LAS CONDES 의 예상 수익 증가율이 절약률( 5.4% )보다 높은지 판단하기에는 데이터가 부족합니다.

수익 vs 시장: LAS CONDES 의 수익이 CL 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: LAS CONDES 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

수익 대 시장: LAS CONDES 의 수익이 CL 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

고성장 수익: LAS CONDES 의 수익이 연간 20% 보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: LAS CONDES 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Clínica Las Condes 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Is Clínica Las Condes (SNSE:LAS CONDES) A Risky Investment?

Less than half of directors are independent

First quarter 2024 earnings released: EPS: CL$61.00 (vs CL$88.57 loss in 1Q 2023)

Returns On Capital At Clínica Las Condes (SNSE:LAS CONDES) Paint A Concerning Picture

Full year 2023 earnings released: CL$406 loss per share (vs CL$483 profit in FY 2022)

Clínica Las Condes S.A.'s (SNSE:LAS CONDES) Business Is Yet to Catch Up With Its Share Price

Now 22% overvalued after recent price rise

Now 22% overvalued after recent price rise

New major risk - Share price stability

Returns On Capital At Clínica Las Condes (SNSE:LAS CONDES) Paint A Concerning Picture

Third quarter 2023 earnings released: CL$419 loss per share (vs CL$136 loss in 3Q 2022)

Is Clínica Las Condes (SNSE:LAS CONDES) A Risky Investment?

Returns At Clínica Las Condes (SNSE:LAS CONDES) Are On The Way Up

New major risk - Financial position

Second quarter 2023 earnings released: EPS: CL$94.00 (vs CL$319 in 2Q 2022)

New major risk - Financial position

Clínica Las Condes (SNSE:LAS CONDES) Is Experiencing Growth In Returns On Capital

Investor sentiment improves as stock rises 17%

Clínica Las Condes (SNSE:LAS CONDES) Takes On Some Risk With Its Use Of Debt

Investor sentiment improves as stock rises 16%

Upcoming dividend of CL$145 per share at 1.3% yield

Investor sentiment improves as stock rises 21%

Full year 2022 earnings released: EPS: CL$483 (vs CL$2,199 in FY 2021)

Third quarter 2022 earnings released: CL$136 loss per share (vs CL$816 profit in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CL$319 (vs CL$850 in 2Q 2021)

Clínica Las Condes (SNSE:LAS CONDES) Is Doing The Right Things To Multiply Its Share Price

First quarter 2022 earnings released: EPS: CL$317 (vs CL$921 in 1Q 2021)

Upcoming dividend of CL$660 per share

No independent directors

There's Been No Shortage Of Growth Recently For Clínica Las Condes' (SNSE:LAS CONDES) Returns On Capital

Full year 2021 earnings released: EPS: CL$2,199 (vs CL$630 loss in FY 2020)

Is Clínica Las Condes (SNSE:LAS CONDES) Using Too Much Debt?

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

There's Been No Shortage Of Growth Recently For Clínica Las Condes' (SNSE:LAS CONDES) Returns On Capital

Investor sentiment improved over the past week

A Look At The Fair Value Of Clínica Las Condes S.A. (SNSE:LAS CONDES)

Second quarter 2021 earnings released: EPS CL$850 (vs CL$882 loss in 2Q 2020)

Does Clínica Las Condes (SNSE:LAS CONDES) Have A Healthy Balance Sheet?

First quarter 2021 earnings released: EPS CL$921 (vs CL$298 loss in 1Q 2020)

Some Investors May Be Worried About Clínica Las Condes' (SNSE:LAS CONDES) Returns On Capital

A Look At Clínica Las Condes' (SNSE:LAS CONDES) Share Price Returns

Full year 2020 earnings released: CL$630 loss per share (vs CL$623 profit in FY 2019)

New 90-day low: CL$22,499

Clínica Las Condes (SNSE:LAS CONDES) Takes On Some Risk With Its Use Of Debt

New 90-day low: CL$23,820

Should You Be Impressed By Clínica Las Condes' (SNSE:LAS CONDES) Returns on Capital?

Third quarter 2020 earnings released: CL$281 loss per share

Clínica Las Condes'(SNSE:LAS CONDES) Share Price Is Down 36% Over The Past Five Years.

New 90-day low: CL$26,721

First half earnings released

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견